Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

NCT06107738 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Iberdomide
DRUG: Daratumumab/rHuPH20 Co-formulation

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]